A STUDY ON SINGLE-SITTING PAN-RETINAL PHOTOCOAGULATION USING MULTISPOT LASER FOR NEWLY DIAGNOSED PROLIFERATIVE DIABETIC RETINOPATHY

Pan-retinal photocoagulation (PRP) is a cornerstone treatment for proliferative diabetic retinopathy (PDR), traditionally performed in multiple sessions. Recent advancements, such as the multispot laser, allow for single-sitting PRP, which may improve patient compliance and streamline care. This study evaluates the safety and efficacy of single-sitting PRP in newly diagnosed PDR patients. A prospective, interventional study was conducted at Father Muller Medical College, Mangalore, involving 35 eyes of patients aged ≥40 years with newly diagnosed PDR. Patients underwent comprehensive ophthalmic evaluation and single-sitting PRP using a multispot laser. Outcomes included changes in best-corrected visual acuity (BCVA), macular thickness (OCT), neovascularization regression, and patient-reported satisfaction. Follow-ups were conducted at 2 weeks, 1 month, and 3 months. BCVAimproved significantly, with 60% of eyes achieving ≥6/18 vision at 1 month (p = 0.020). Neovascularization regressed in 67.6% of cases within 1 month, with stabilization achieved in 91.4%. No significant macular edema or adverse events were observed, and pain scores were minimal (mean: 0.89 ± 0.53). Higher HbA1c levels correlated with slower neovascular regression (p = 0.035). Patient satisfaction was high (94%), citing reduced anxiety and convenience. Single-sitting PRP with a multispot laser is safe and effective for managing PDR, offering significant improvements in BCVA, high neovascular regression rates, and minimal discomfort. This approach enhances patient adherence and reduces the treatment burden, especially in resource-limited settings. Future research should explore long-term outcomes and potential combination therapies.